MedPath

Gemcitabine With or Without CI-994 in Treating Patients With Advanced Non-small Cell Lung Cancer

Phase 3
Completed
Conditions
Lung Cancer
Registration Number
NCT00005093
Lead Sponsor
Pfizer
Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether gemcitabine plus CI-994 is more effective than gemcitabine alone for non-small cell lung cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of gemcitabine with or without CI-994 in treating patients who have advanced non-small cell lung cancer.

Detailed Description

OBJECTIVES: I. Determine the efficacy and safety of gemcitabine with or without CI-994 in patients with advanced non-small cell lung cancer.

OUTLINE: This is a randomized, double blind, placebo controlled, multicenter study. Patients are stratified according to performance status and are randomized to one of two treatment arms. Arm I: Patients receive CI-994 orally on days 1-21 and gemcitabine IV over 30 minutes on days 1, 8, and 15. Arm II: Patients receive placebo capsules orally on days 1-21 and gemcitabine as in arm I. Treatment repeats every 28 days as long as medically appropriate (absence of disease progression or unacceptable toxicity).

PROJECTED ACCRUAL: A total of 176 patients will be accrued for this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (16)

New England Medical Center Hospital

πŸ‡ΊπŸ‡Έ

Boston, Massachusetts, United States

BC Cancer Agency

πŸ‡¨πŸ‡¦

Vancouver, British Columbia, Canada

University of Michigan Comprehensive Cancer Center

πŸ‡ΊπŸ‡Έ

Ann Arbor, Michigan, United States

Barbara Ann Karmanos Cancer Institute

πŸ‡ΊπŸ‡Έ

Detroit, Michigan, United States

Cross Cancer Institute

πŸ‡¨πŸ‡¦

Edmonton, Alberta, Canada

Mount Sinai Hospital - Toronto

πŸ‡¨πŸ‡¦

Toronto, Ontario, Canada

West Clinic, P.C.

πŸ‡ΊπŸ‡Έ

Memphis, Tennessee, United States

British Columbia Cancer Agency - Vancouver Island Cancer Centre

πŸ‡¨πŸ‡¦

Victoria, British Columbia, Canada

Arthur G. James Cancer Hospital - Ohio State University

πŸ‡ΊπŸ‡Έ

Columbus, Ohio, United States

Raleigh Hematology/Oncology Associates - Wake Practice

πŸ‡ΊπŸ‡Έ

Raleigh, North Carolina, United States

Princess Margaret Hospital

πŸ‡¨πŸ‡¦

Toronto, Ontario, Canada

H. Lee Moffitt Cancer Center and Research Institute

πŸ‡ΊπŸ‡Έ

Tampa, Florida, United States

Cedars-Sinai Comprehensive Cancer Center

πŸ‡ΊπŸ‡Έ

Los Angeles, California, United States

Southwest Regional Cancer Center

πŸ‡ΊπŸ‡Έ

Austin, Texas, United States

British Columbia Cancer Agency - Fraser Valley Cancer Centre

πŸ‡¨πŸ‡¦

Surrey, British Columbia, Canada

Ottawa Regional Cancer Center - General Division

πŸ‡¨πŸ‡¦

Ottawa, Ontario, Canada

Β© Copyright 2025. All Rights Reserved by MedPath